Principal Investigators: 
Award Amount: 
£119,960

Drugs which work well for some patients with soft tissue sarcoma can, in other patients, only work for a short time, or not work at all. This project is investigating why different cases of soft tissue sarcoma respond so differently to the same drugs. If you can accurately predict how a patient will respond to treatment, no crucial time is wasted.

Defining the mechanisms of pazopanib and regorafenib resistance in soft tissue sarcoma- 'Sayako Grace Robinson Studentship'

Pazopanib and regorafenib are drugs which are effective in the treatment of advanced soft tissue sarcoma. However, there are some patients who do not respond to treatment with these drugs and in other patients, the effect of the drugs can wear off as cancer develops resistance.

This research is looking to discover the biological features of soft tissue sarcoma to understand why some patients don’t respond to pazopanib and regorafenib or become resistance to their effects. The project goals are to develop a test which will identify the patients who are most likely to respond to treatment; and how best to prevent and treat drug resistance in soft tissue sarcoma tumours.

The project will study tumour samples collected from patients who have been treated with pazopanib, the team have identified a molecular signature that is associated with drug resistance and poor treatment effect. The project involves modelling this molecular signature in sarcoma cell lines, allowing the researchers to study the complex biological processes that determine whether the cells are affected by pazopanib and regorafenib.

This project will provide the basis for new clinical trials that will help doctors to test how patients may respond to drugs before a treatment is given. It will also provide knowledge into how to overcome drug resistance in soft tissue sarcoma.

 

Read more about the Sayako Grace Robinson Studentships

Project status: 
open